Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

EDESA BIOTECH, INC.

(EDSA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Edesa Biotech, Inc. Announces Positive Phase 2 Data of Monoclonal Antibody in Hospitalized Covid-19 Patients

09/20/2021 | 01:12pm BST

Edesa Biotech, Inc. announced positive results from the Phase 2 part of an ongoing Phase 2/3 clinical study evaluating the company's monoclonal antibody candidate as a single-dose treatment for hospitalized COVID-19 patients. An independent Data and Safety Monitoring Board (DSMB), composed of subject matter experts, informed the company that during its initial analysis of the Phase 2 portion of the study they identified an important signal between the treatment arms for 28-day mortality, and requested that the study be preemptively unblinded. While the Phase 2 portion was primarily designed to refine patient stratification and statistical powering for the Phase 3 study, the DSMB concluded that "a clinically important efficacy signal" was detected and that the study has "met its objective." The DSMB further recommended continuation of the study into a Phase 3 confirmatory trial. Among the findings, the DSMB reported a Cox's Proportional Hazard estimate for death of 14.3% (2/14) in the EB05 arm versus 36.8% (7/19) in the placebo arm, representing a 217% improvement in the relative likelihood of survival (HR: 3.17; 95%CI: 0.66-15.35; p=0.15) in critically severe patients on ECMO therapy (extracorporeal membrane oxygenation) with or without invasive mechanical ventilation, at 28 days versus Standard of Care treatment alone. Approximately 100% of patients received dexamethasone (or other steroids), 60% received tocilizumab, and 60% received both, balanced across both arms of the study. The results from the Phase 2 analysis also suggest that EB05 has been generally well-tolerated and consistent with the observed safety profile to date. In addition, the DSMB identified another patient group with robust signals for mortality reduction at 28 days and the company plans to review this data as well as the full dataset. The analysis reviewed data from approximately 360 patients, 24 to 93 years of age, from investigational sites in the United States, Canada and Colombia. Participants were treated with a single intravenous infusion of either EB05 plus standard of care treatment, or placebo plus standard of care (randomized 1:1). The DSMB's initial analysis was limited to the mortality endpoint, and a review of other endpoints is ongoing.


ę S&P Capital IQ 2021
All news about EDESA BIOTECH, INC.
10/19EDESA BIOTECH : Says its COVID-19 Drug Candidate Reduces Mortality, Based on Phase 2 Study..
MT
10/19EDESA BIOTECH : Reports Favorable Mortality Reductions in COVID-19 Study
PU
10/19Edesa Biotech Reports Favorable Mortality Reductions in Covid-19 Study
CI
09/20Top Midday Gainers
MT
09/20Edesa Biotech Sees Positive Results From Study for Covid-19 Treatment
DJ
09/20Top Premarket Gainers
MT
09/20EDESA BIOTECH : Announces Positive Phase 2 Data of Its Monoclonal Antibody in Hospitalized..
PU
09/20Edesa Biotech, Inc. Announces Positive Phase 2 Data of Monoclonal Antibody in Hospitali..
CI
09/09EDESA BIOTECH : to Present at the H.C. Wainwright Global Investment Conference
PU
08/26EDESA BIOTECH : Achieves Enrollment Milestone in Phase 2/3 Trial of COVID-19 Monoclonal An..
MT
More news
Financials
Sales 2021 - - -
Net income 2021 -15,7 M - -11,4 M
Net Debt 2021 - - -
P/E ratio 2021 -6,55x
Yield 2021 -
Capitalization 102 M 102 M 74,1 M
Capi. / Sales 2021 -
Capi. / Sales 2022 4,17x
Nbr of Employees 12
Free-Float 71,2%
Chart EDESA BIOTECH, INC.
Duration : Period :
Edesa Biotech, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EDESA BIOTECH, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 7,70 $
Average target price 19,00 $
Spread / Average Target 147%
EPS Revisions
Managers and Directors
Pardeep Nijhawan Chief Executive Officer, Secretary & Director
Michael Brooks President
Kathi Niffenegger Chief Financial Officer
Sean A. MacDonald Chairman
Blair Gordon Vice President-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
EDESA BIOTECH, INC.81.18%102
GILEAD SCIENCES, INC.15.41%84 306
BIONTECH SE241.44%67 225
WUXI APPTEC CO., LTD.24.51%64 578
REGENERON PHARMACEUTICALS18.47%59 507
VERTEX PHARMACEUTICALS-22.35%47 610